<DOC>
	<DOCNO>NCT02552953</DOCNO>
	<brief_summary>This open-label , single arm , dose escalation study patient advance cancer .</brief_summary>
	<brief_title>A Pharmacologic Study CYC065 , Cyclin Dependent Kinase Inhibitor , Patients With Advanced Cancers</brief_title>
	<detailed_description>This open-label , single arm , dose escalation study patient advance cancer . Treatment administer outpatient basis .</detailed_description>
	<mesh_term>Cyclin-Dependent Kinase Inhibitor Proteins</mesh_term>
	<criteria>Histologically cytologically confirm solid tumor lymphomas metastatic unresectable standard curative palliative measure exist longer effective 18 year old ECOG performance status 01 Life expectancy â‰¥ 3 month Evaluable disease Adequate organ function 4 week prior chemotherapy ( 6 week mitomycin C nitrosourea ) , immunotherapy , investigational anticancer therapy , radiation therapy ; recover prior toxicity At least 4 week major surgery Agree practice effective contraception Agree follow protocol require evaluation Ability understand willingness sign inform consent form Previously untreated CNS metastasis progressive CNS metastasis Currently receive radiotherapy , biological therapy , investigational agent Uncontrolled intercurrent illness Pregnant lactate woman Known HIVpositive Known active hepatitis B and/or hepatitis C infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>